Compare Dollar Tree, Inc. (DLTR) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Heron Therapeutics Inc — how do they compare? Dollar Tree, Inc. trades at $118.65 (market cap $21.82B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Dollar Tree, Inc. is far larger — about 294.7× Heron Therapeutics Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Heron Therapeutics Inc for 35 Days on average.
| DLTR | HRTX | |
|---|---|---|
Market Cap | $21.82B | $74.04M |
Volume | 1,613,659 | 3,668,095 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $1.49 |
52-Week Low | $86.80 | $0.27 |
Typical Hold Time | 58 Days | 35 Days |
Enterprise Value | $28.43B | $180.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $118.62, up 2.09% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 45.87% ROE and trades at a modest P/E of 14.25. Recent news highlights strategic initiatives and store expansions driving growth, though margin risks from tariffs and costs persist. Cash flow trends are positive, with 2025 net cash flow reaching $754 million.
Outlook is positive with a consensus price target of $139.33, implying 17% upside. Key opportunities include continued earnings momentum and store improvements, while risks involve margin pressure from tariffs and reinvestment costs. Analyst sentiment is bullish with 53% buy ratings, but investors should monitor execution on profitability targets.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
